Journal Supplement
- Optimal pharmacotherapy to combat the atherogenic lipid triad.
- Healthy food and healthy choices: a new European profile approach.
- Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine.
- Clinical experience with the novel histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in patients with relapsed lymphoma.
- Programmatic issues in the implementation of an HPV vaccination program to prevent cervical cancer.
- Correlating immunity with protection for HPV infection.
- Human papillomavirus infection and the development of cervical cancer and related genital neoplasias.
- The Lorenzini Foundation in a changing scenario of patient management.
- Bridging science and health policy in cardiovascular disease: focus on lipid management.
- Barriers to multiple risk factor management in cardiovascular disease.
- Clinical and laboratory experience of vorinostat (suberoylanilide hydroxamic acid) in the treatment of cutaneous T-cell lymphoma.
- Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor.
